<DOC>
	<DOCNO>NCT00257192</DOCNO>
	<brief_summary>The purpose study determine flexibly-dosed ziprasidone safe effective treatment adolescent ( age 13-17 ) schizophrenia</brief_summary>
	<brief_title>Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia</brief_title>
	<detailed_description>Termination Reason : On March 24 , 2009 , Pfizer Inc. stop late stage Geodon pediatric clinical trial schizophrenia ( A1281134 - placebo control ; A1281135 - open label ) . As recommended DSMB , study stop due lack efficacy . No safety concern identify .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criterion schizophrenia : Current symptom present least 7 day screen . At Screening Baseline visit , subject must Brief Psychiatric Rating Scale Anchored score ≥35 score ≥4 least 1 follow item : unusual thought content ( i.e. , delusion ) , hallucination , suspiciousness , conceptual disorganization . Age 13 17 year Imminent risk suicide homicide , judge site investigator Any history serious unstable medical illness , include risk QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Adolescent Subjects With Schizophrenia</keyword>
</DOC>